Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways
批准号:
10396610
负责人:
Shridar Ganesan
金额:
$38.82万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-05-01 至 2023-04-30
关键词:
AcetylationAddressAffectBMI1 geneBRCA1 geneBRCA2 geneBindingCell SurvivalCellsCellular biologyChromatinChromatin Remodeling FactorClinicalComputational BiologyDNADNA DamageDNA RepairDNA Repair PathwayDefectDevelopmentDrug TargetingEngineeringEventGene SilencingGenetic TranscriptionGenomicsHistonesHumanImpairmentLeadLocationMalignant NeoplasmsMediatingMethodsMethyltransferaseModificationMolecular BiologyMusMutationPALB2 genePathway interactionsPhenotypePhosphorylationPlayPost-Translational Protein ProcessingProteinsRegulationRepair ComplexRoleSerineSignal PathwaySignal TransductionSiteSystemTranscriptional RegulationTransferaseUbiquitinationchromatin modificationclinically relevantgenome editinghistone methylationhistone modificationinhibitorinnovationinsightknock-downmembermutantp53-binding protein 1recruitrepairedresponsesmall moleculesmall molecule inhibitortargeted treatmenttherapeutic targettreatment responsetumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT:
Induction of a DNA break initiates DNA damage signaling pathways that lead to coordinated and dynamic
modification of the local chromatin landscape, including regulated changes in post-translational modification of
histones flanking the site of DNA damage. These chromatin changes are required to recruit repair complexes
to the site of damage, and repress transcription of genes flanking the break during repair. We recently found
that euchromatic histone methyl transferase 2 (EHMT2, also known as G9a) plays a crucial role in regulating
DNA repair. EHMT2 is rapidly recruited to sites of DNA breaks in a manner dependent on its phosphorylation
by ATM at serine 569. Interestingly, the methyl-transferase activity of EHMT2 is required for the early, H2AX-
independent recruitment of DNA repair factors including RNF8, 53BP1 and BRCA1; We have also recently
found that EHMT2 activity is required for normal regulation of key features of ATM-mediated induction of
transcriptional silencing near a DNA break. This includes regulation and recruitment of key silencing factors
such as BMI1 and CDYL. These findings suggest that EHMT2 has a key role in regulating both DNA repair
efficiency and modulating transcriptional regulation near a DNA break. As small molecule inhibitors of EHMT2
are now being developed for clinical use, EHMT2 may be one of the components of the DNA repair pathway
that may be therapeutically targetable. We hypothesize that EHMT2 activity during the DNA damage response
is 1) required to mediate local transcriptional silencing by regulating both histone and non-histone substrates 2)
enables the early, H2AX independent, recruitment of DNA repair factors to sites of DNA damage through the
action of key binding partners and substrates and 3) is critical for cell survival in the presence of specific
cancer-associated DNA repair defects. These hypotheses will be investigated through the following set of
specific aims. Aim 1. Determine the role of EHMT2 in DNA-damage-induced transcriptional silencing. Aim 2:
Determine role of EHMT2 in H2AX-indpendent recruitment of DNA repair factors. Aim 3: Define synthetic lethal
interactions of EHMT2 in DNA repair and chromatin regulation. To address these aims we will use carefully
interrogate the effect of EHMT2 loss and inhibition on multiple aspects of DNA repair and local chromatin
landscape near a DNA break. This will be done in cell and mouse systems where induction of DNA damage is
engineered at specific genomic locations, and the effect of DNA damage on local chromatin landscape and
recruitment of DNA repair factors can be systematically interrogated. We will also determine how EHMT2
inhibition using small molecule catalytic inhibitors perturbs repair pathway and survival in both wt cells and
cells harboring specific, clinically relevant mutations in DNA repair pathways, including ATM, BRCA1, PALB2
and BRCA2. By this approach we will gain new insight into the fundamental role of EHMT2 in regulating DNA
repair, and develop synthetic lethal strategies to target cancers harboring specific defects in DNA repair or
chromatin regulation with EHMT2 inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3: Chromatin modifiers of BRCA-related DNA repair Pathways
-
批准号:10599902
-
项目类别:
-
资助金额:$38.7万
-
财政年份:2021
-
负责人:Shridar Ganesan
-
依托单位:
Impact of mutation burden on cancer growth and the immune landscape
-
批准号:10295769
-
项目类别:
-
资助金额:$63.32万
-
财政年份:2019
-
负责人:Shridar Ganesan
-
依托单位:
Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironment
-
批准号:10393564
-
项目类别:
-
资助金额:$64.29万
-
财政年份:2019
-
负责人:Shridar Ganesan
-
依托单位:
Impact of mutation burden on cancer growth and the immune landscape
-
批准号:9914625
-
项目类别:
-
资助金额:$64.44万
-
财政年份:2019
-
负责人:Shridar Ganesan
-
依托单位:
Impact of mutation burden on cancer growth and the immune landscape
-
批准号:10063504
-
项目类别:
-
资助金额:$64.44万
-
财政年份:2019
-
负责人:Shridar Ganesan
-
依托单位:
Evolution and clinical impact of clonal hematopoiesis of indeterminate potential in breast tumor microenvironment
-
批准号:10610871
-
项目类别:
-
资助金额:$63.01万
-
财政年份:2019
-
负责人:Shridar Ganesan
-
依托单位:
Impact of mutation burden on cancer growth and the immune landscape
-
批准号:10527356
-
项目类别:
-
资助金额:$63.56万
-
财政年份:2019
-
负责人:Shridar Ganesan
-
依托单位:
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
-
批准号:9091478
-
项目类别:
-
资助金额:$32.93万
-
财政年份:2012
-
负责人:Shridar Ganesan
-
依托单位:
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
-
批准号:8538332
-
项目类别:
-
资助金额:$30.95万
-
财政年份:2012
-
负责人:Shridar Ganesan
-
依托单位:
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
-
批准号:8343745
-
项目类别:
-
资助金额:$34.19万
-
财政年份:2012
-
负责人:Shridar Ganesan
-
依托单位:
Decision Support System for Predicting outcome of ER+ breast cancers
-
批准号:8123523
-
项目类别:
-
资助金额:$20.71万
-
财政年份:2011
-
负责人:Shridar Ganesan
-
依托单位:
P-1: Biology and Treatment of BRCA1-Associated and Sporadic Basal-like Cancers
-
批准号:6966193
-
项目类别:
-
资助金额:$7.18万
-
财政年份:2005
-
负责人:Shridar Ganesan
-
依托单位:
BRCA1 AND X CHROMOSOME INACTIVATION
-
批准号:6815336
-
项目类别:
-
资助金额:$13.37万
-
财政年份:2004
-
负责人:Shridar Ganesan
-
依托单位:
BRCA1 AND X CHROMOSOME INACTIVATION
-
批准号:7067913
-
项目类别:
-
资助金额:$15.53万
-
财政年份:2004
-
负责人:Shridar Ganesan
-
依托单位:
BRCA1 AND X CHROMOSOME INACTIVATION
-
批准号:7288694
-
项目类别:
-
资助金额:$15.53万
-
财政年份:2004
-
负责人:Shridar Ganesan
-
依托单位:
BRCA1 AND X CHROMOSOME INACTIVATION
-
批准号:6942622
-
项目类别:
-
资助金额:$15.53万
-
财政年份:2004
-
负责人:Shridar Ganesan
-
依托单位:
BRCA1 AND X CHROMOSOME INACTIVATION
-
批准号:7468417
-
项目类别:
-
资助金额:$15.53万
-
财政年份:2004
-
负责人:Shridar Ganesan
-
依托单位:
Comprehensive Genomics
-
批准号:10112862
-
项目类别:
-
资助金额:$5.68万
-
财政年份:1997
-
负责人:Shridar Ganesan
-
依托单位:
Clinical Investigations and Precision Therapeutics
-
批准号:10580690
-
项目类别:
-
资助金额:$7.01万
-
财政年份:1997
-
负责人:Shridar Ganesan
-
依托单位:
Comprehensive Genomics
-
批准号:10357805
-
项目类别:
-
资助金额:$3.79万
-
财政年份:1997
-
负责人:Shridar Ganesan
-
依托单位:
海外基金